Pfizer — NovaMedica: the Bargain Accomplished
An agreement on long-term strategic partnership has been concluded between Russian company NovaMedica and American Pfizer. The agreement concerns transfer of technology of manufacture of over 30 vital and essential drugs from the portfolio of Pfizer.
Manufacturing facility being built in the Kaluga region involving Pfizer will be equipped according to the international and Russian standards of quality, including good manufacturing practice (GMP) Rules. It will help NovaMedica enter international markets, as products manufactured at the new site, will be exported abroad. It is also supported by the fact that Pfizer shall pass to the Russian partner technologies of manufacture of over 30 sterile injectable products, which will be manufactured at the new NovaMedica site. It includes products for treatment of severe bacterial and fungal infections, cardiovascular, inflammatory and neoplastic disorders.